TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察(1)
摘 要：目的 探讨紫杉醇+顺铂化疗方案联合回生口服液治疗中晚期NSCLC的疗效。方法 选取2014年1月～2017年5月于我院就诊的中晚期NSCLC患者68例，随机分为观察组和对照组，每组34例。对照组予以TP方案(紫杉醇+顺铂)治疗，观察组予以TP方案联合回生口服液治疗，对比两组患者的临床疗效、不良反应、血清VEGF、IL-6、MMP-9水平和生存时间、生活质量。结果 观察组的治疗总有效率为70.59%，高于对照组的55.89%，差异具有统计学意义(P<0.05)。观察组治疗后的VEGF、IL-6、MMP-9水平均低于对照组，差异具有统计学意义(P<0.05)。观察组治疗后的生活质量评分高于对照组，差异具有统计学意义(P<0.05)。观察组的肿瘤进展时间为(5.46±2.76)个月、生存时间(11.04±0.82)个月，少于对照组的肿瘤进展时间为(4.15±2.15)个月、生存时间(8.12±0.64)个月(Log Rank： statistic=4.15，P=0.037)。观察组不良反应率为20.59%，低于對照组的41.18%，差异具有统计学意义(P<0.05)。结论 TP方案联合回生口服液治疗中晚期NSCLC的临床疗效良好，可有效改善中晚期NSCLC患者的炎症状态，抑制肿瘤心血管生成，提高肿瘤细胞杀伤能力，临床疗效显著，安全性高，患者治疗后的生存期有效延长，生活质量明显提高。
, http://www.100md.com
关键词：非小细胞肺癌；TP方案；回生口服液
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.17.005
文章编号：1006-1959(2018)17-0017-03
Abstract：Objective To investigate the efficacy of paclitaxel+cisplatin chemotherapy combined with Huisheng oral liquid in the treatment of advanced NSCLC.Methods A total of 68 patients with advanced NSCLC who were admitted to our hospital from January 2014 to May 2017 were randomly divided into observation group and control group，with 34 cases in each group.The control group was treated with TP regimen(paclitaxel+cisplatin)，and the observation group was treated with TP regimen combined with Huisheng oral liquid.The clinical efficacy，adverse reactions，serum VEGF，IL-6，MMP-9 levels，survival time and quality of life were compared between the two groups.Results The total effective rate of the observation group was 70.59%，which was higher than that of the control group 55.89%，the difference was statistically significant(P<0.05).The levels of VEGF，IL-6 and MMP-9 in the observation group were lower than those in the control group，the difference was statistically significant(P<0.05).The quality of life scores of the observation group after treatment were higher than those of the control group，the difference was statistically significant(P<0.05).The tumor progression time of the observation group was(5.46±2.76)months and survival time(11.04±0.82)months，and the tumor progression time was less than(4.15±2.15)months and survival time(8.12±0.64)month(Log Rank：statistic=4.15，P= 0.037).The adverse reaction rate of the observation group was 20.59%，which was lower than that of the control group 41.18%and the difference was statistically significant(P<0.05).Conclusion TP regimen combined with Huisheng oral liquid is effective in the treatment of advanced NSCLC.It can effectively improve the inflammatory state of patients with advanced NSCLC，inhibit tumor cardiovascular production，improve tumor cell killing ability，clinical efficacy is significant，and safety is high.After treatment the survival period is effectively extended and the quality of life is significantly improved., 百拇医药(杨莉)
, http://www.100md.com
关键词：非小细胞肺癌；TP方案；回生口服液
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.17.005
文章编号：1006-1959(2018)17-0017-03
Abstract：Objective To investigate the efficacy of paclitaxel+cisplatin chemotherapy combined with Huisheng oral liquid in the treatment of advanced NSCLC.Methods A total of 68 patients with advanced NSCLC who were admitted to our hospital from January 2014 to May 2017 were randomly divided into observation group and control group，with 34 cases in each group.The control group was treated with TP regimen(paclitaxel+cisplatin)，and the observation group was treated with TP regimen combined with Huisheng oral liquid.The clinical efficacy，adverse reactions，serum VEGF，IL-6，MMP-9 levels，survival time and quality of life were compared between the two groups.Results The total effective rate of the observation group was 70.59%，which was higher than that of the control group 55.89%，the difference was statistically significant(P<0.05).The levels of VEGF，IL-6 and MMP-9 in the observation group were lower than those in the control group，the difference was statistically significant(P<0.05).The quality of life scores of the observation group after treatment were higher than those of the control group，the difference was statistically significant(P<0.05).The tumor progression time of the observation group was(5.46±2.76)months and survival time(11.04±0.82)months，and the tumor progression time was less than(4.15±2.15)months and survival time(8.12±0.64)month(Log Rank：statistic=4.15，P= 0.037).The adverse reaction rate of the observation group was 20.59%，which was lower than that of the control group 41.18%and the difference was statistically significant(P<0.05).Conclusion TP regimen combined with Huisheng oral liquid is effective in the treatment of advanced NSCLC.It can effectively improve the inflammatory state of patients with advanced NSCLC，inhibit tumor cardiovascular production，improve tumor cell killing ability，clinical efficacy is significant，and safety is high.After treatment the survival period is effectively extended and the quality of life is significantly improved., 百拇医药(杨莉)